Orforglipron
Non-peptide (small-molecule) GLP-1 receptor agonist, oral
Also known as LY3502970, OWL833
Typical dose
3 / 12 / 36 mg
once daily · oral tablet
Half-life
supports once-daily dosing
What is Orforglipron?
A first-in-class ORAL, non-peptide small-molecule GLP-1 receptor agonist (Eli Lilly, LY3502970) for obesity and type 2 diabetes. A daily pill — no injection, no empty-stomach requirement (unlike oral semaglutide).
How Orforglipron works
A non-peptide allosteric GLP-1 receptor agonist — binds the transmembrane core (not the extracellular domain the native peptide uses), which is why a small molecule works orally. Biased toward metabolic-efficacy signaling.
Benefits & uses
- Weight loss (~5–8% at 40 wks in trials)
- Strong blood-sugar control (HbA1c ~6.5%)
- ORAL — no injection
- No empty-stomach requirement
Common uses: Fat loss / obesity, type 2 diabetes (oral option).
Orforglipron dosage
Protokol doesn't recommend doses for prescription or controlled compounds. Any figures below are reference or observational reports — dosing should be set with a qualified clinician.
- Typical dose
- 3 mg, 12 mg, or 36 mg once daily (trial doses); titrated up. Phase 2 tested 3–45 mg/day.
Orforglipron half-life
supports once-daily dosing
Orforglipron side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation (GLP-1 class GI effects)
Warnings & monitoring
- GLP-1 class risks: pancreatitis, gallbladder, thyroid C-cell caution
- Titrate to reduce GI effects
- Not for pregnancy
Preparation & storage
- Reconstitution
- Oral — no reconstitution.
Track Orforglipron in Protokol.
Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.
